HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prilosec 24-Hour Acid Control Would Be Unique To OTC Category

This article was originally published in The Tan Sheet

Executive Summary

Once-a-day dosing of heartburn remedy Prilosec could be highlighted by AstraZeneca/Proctor & Gamble as a competitive advantage over other OTC stomach therapies if an Rx-to-OTC switch of the proton pump inhibitor were approved by FDA.

You may also be interested in...

Prilosec Rx Ad Spend Jumps As OTC Switch Review Approaches

AstraZeneca dedicated $62.2 mil. to DTC advertising for Rx Prilosec (omeprazole) in the first six months of 2000, according to measured media spending data from Competitive Media Reporting.

OTC Treatment Of Nighttime Heartburn Partially Helpful - Gastroenterologist

Self-treatment of nighttime heartburn with OTC drugs will protect only about one-third of sufferers from potentially serious medical conditions, Donald Castell, MD, The Graduate Hospital, Philadelphia, opined Aug. 24.


FDA's Nonprescription and Gastrointestinal Drugs Advisory Committees will meet jointly Oct. 20 to consider AstraZeneca's NDA 21-229 to switch its blockbuster drug Prilosec (omeprazole) OTC; the nonprescription product would be distributed by Procter & Gamble. Proposed indications the committees will review are: "To relieve heartburn, acid indigestion and sour stomach" and "To prevent heartburn, acid indigestion and sour stomach brought on by consuming foods and beverages or associated with events such as stress, hectic lifestyle, lying down or exercise." On Oct. 19, NDAC will consider the safety of phenylpropanolamine, giving attention to a CHPA-sponsored Yale study on the risk of hemorrhagic stroke and PPA (1"The Tan Sheet" May 29, p. 11)

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts